@article{355715f189ef4a118585be1fb05883a6,
title = "Contemporary use of clopidogrel in patients with coronary artery disease",
abstract = "Antiplatelet agents have long served as the cornerstone of pharmacologic therapy to prevent atherothrombotic events. The thienopyridines have risen to prominence as both an alternative and adjunctive treatment to aspirin monotherapy. These agents prevent platelet aggregation by selectively and irreversibly blocking the platelet ADP P2Y12 receptor. In this article we focus on the use of clopidogrel in the contemporary management of coronary artery disease. We assess the use of clopidogrel following revascularization for coronary artery disease with percutaneous coronary intervention, particularly after deployment of drug-eluting stents. Finally, we address some aspects of clopidogrel resistance.",
author = "Parikh, {Sahil A.} and Beckman, {Joshua A.}",
note = "Funding Information: Papers of particular interest, published recently, have been highlighted as: 9 Of importance 9 * Of major importance 1. Fuster V, Moreno PR, Fayad ZA, et al.: Atherothrombosis and high-risk plaque: part h evolving concepts. J Am Coll Cardio12005, 46:937-954. Patrono C, Garcia Rodriguez LA, Landolfi R, et al.: Low-dose aspirin for the prevention of atherothrombosis. N EnglJ Med 2005, 353:2373-2383. Hirsch AT, Haskal ZJ, Hertzer NR, et al.: ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesen-teric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiog-raphy and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006, 113:e463-e654. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Tran H and Anand SS: Oral antiplatelet therapy in cerebro-vascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004, 292:1867-1874. Eshaghian S, Kaul S, Amin S, et al.: Role of clopidogrel in managing atherothrombotic cardiovascular disease. Ann Intern Med 2007, 146:434-441. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348:1329-1339. Gaspoz JM, Coxson PG, Goldman PA, et al.: Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002, 346:1800-1806. Clagett GP, Sobel M, Jackson MR, et al.: Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:609S-626S. 10. Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502. 11..* Sabatine MS, Cannon CP, Gibson CM, et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N EnglJ Med 2005, 352:1179-1189. The CLARITY-TIMI 28 trial demonstrated the efficacy of clopidogrel in ACS in those patients with STEMI when treated with fibrinolytic therapy. 12.-. Chen ZM, Jiang LX, Chen YP, et al.: Addition of clopidogrel to aspirin in 45,852 patients with acute 9 myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1607-1621. The COMMIT trial similarly demonstrated reduction of cardiovascular events in patients with STEMI with clopidogrel, 75 mg/d, without a loading dose. 13. Steinhubl SR, Berger PB, Mann JT 3rd, et al.: Early and sustained dual oral antiplatelet therapy following percuta-neons coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.",
year = "2007",
month = jul,
doi = "10.1007/BF02938373",
language = "English (US)",
volume = "9",
pages = "257--263",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "4",
}